Onconetix authorized 42,000 shares of Series F Convertible Preferred Stock to be issued pursuant to a securities purchase agreement, with voting, dividend, and liquidation rights.
Onconetix authorized 42,000 shares of Series F Convertible Preferred Stock to be issued pursuant to a securities purchase agreement, with voting, dividend, and liquidation rights.